Are polymorphisms of the β3-adrenoceptor gene associated with an altered bladder function?

Neurourology and Urodynamics

Volumn 32, Issue 3, 2013, Pages 276-280

  Teitsma, Christine A ^a   De La Rosette, Jean J M C H ^a   Michel, Martin C ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

3 adrenoceptor; bladder function; gene polymorphism

Indexed keywords

ARGININE; BETA 3 ADRENERGIC RECEPTOR; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALLELE; ARTICLE; BLADDER COMPLIANCE; BLADDER FUNCTION; DNA POLYMORPHISM; GENE SEQUENCE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; PROSTATE SIZE; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HOSPITALS, UNIVERSITY; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; NETHERLANDS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PRESSURE; PROSTATIC HYPERPLASIA; RECEPTORS, ADRENERGIC, BETA-3; RISK FACTORS; URINARY BLADDER; URODYNAMICS;

EID: 84875382377     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.22305     Document Type: Article

References (34)

1. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 2006; 50: 1306-15.
2. Hannestad YS, Lie RT, Rortveit G, et al. Familial risk of urinary incontinence in women: Population based cross sectional study. Br Med J 2004; 329: 889-91.
3. Rohr G, Kragstrup J, Gaist D, et al. Genetic and environmental influences on urinary incontinence: A Danish populations-based twin study of middle-aged and elderly women. Acta Obstet Gynecol Scand 2004; 83: 978-82.
4. Norton P, Milsom I,. Genetics and the lower urinary tract. Neurourol Urodyn 2010; 29: 609-11.
5. Schwanke CHA, Bittencourt L, Noronha JAP, et al. Is there an association between T102C polymorphism of the serotonin receptor 2A gene and urinary incontinence ? Braz J Med Biol Res 2007; 40: 1315-22.
6. Honda K, Nomiya M, Shishido K, et al. Mutation of β3-adrenoceptor gene: A genetic marker for overactive bladder. Neurourol Urodyn 2006; 25: 652.
7. 3- adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: Analysis by molecular biological and pharmacologocial methods. J Pharmacol Exp Ther 1999; 288: 1367-73.
8. 2- and β-Adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006; 147: S88-119.
9. 3-Adrenoceptors in urinary bladder. Neurourol Urodyn 2007; 26: 752-6.
10. Michel MC, Ochodnicky P, Homma Y, et al. β-Adrenoceptor agonist effects in experimental models of bladder dysfunction. Pharmacol Ther 2011; 131: 40-9.
11. Khullar V, Ströberg P, Anuglo J, et al. The efficacy and tolerability of mirabegron in patients with overactive bladder-Results from a European-Australian phase III trial. Eur Urol Suppl 2011; 10: 278-9.
12. Nitti V, Herschorn S, Auerbach S, et al. The efficacy and safety of mirabegron in patients with overactive bladder syndrome-Results from a North-American phase III trial. Eur Urol Suppl 2011; 10: 278.
13. 3-adrenoceptor agonist solabegron for overactive bladder. Eur Urol 2012; in press DOI: 10.1016/j.eururo.2012.05.053
14. 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. New Engl J Med 1995; 333: 352-4.
15. 3-adrenergic receptor gene. New Engl J Med 1995; 333: 343-7.
16. 3-adrenergic receptor mutant. Endocrinology 1996; 137: 2638-41.
17. Pietri-Rouxel F, St John Manning B, Gros J, et al. The biochemical effect of the naturally occurring Trp64->Arg mutation on human beta3-adrenoceptor activity. Eur J Biochem 1997; 247: 1174-9.
18. Kimura K, Sasaki N, Asano A, et al. Mutated human β3-adrenergic receptor (Trp64Arg) lowers the response to β3-adrenergic agonists in transfected 3T3-L1 preadipocytes. Horm Metab Res 2000; 32: 91-6.
19. 3-adrenergic receptor. Jpn J Pharmacol 2002; 88: 314-8.
20. 3-adrenoceptors ? Br J Pharmacol 2009; 156: 127-34.
21. Leineweber K, Büscher R, Bruck H, et al. β-Adrenoceptor polymorphisms. Naunyn-Schmiedeberg's Arch Pharmacol 2004; 369: 1-22.
22. Souverein PC, Erkens JA, de la Rosette JJMCH, et al. Drug treatment of benign prostatic hyperplasia and hospital admission for BPH-related surgery. Eur Urol 2003; 43: 528-34.
23. Halushka MK, Fan J-B, Bentley K, et al. Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat Genet 1999; 22: 239-47.
24. Sountoulides P, van Dijk MM, Wijkstra H, et al. Role of voiding and storage symptoms for the quality of life before and after treatment in men with voiding dysfunction. World J Urol 2009; 28: 3-8.
25. van Dijk MM, Wijkstra H, Debruyne F, et al. The role of nocturia in the quality of life of men with lower urinary tract symptoms. BJU Int 2010; 105: 1141-6.
26. Insel PA, Tang C-M, Hahntow I, et al. Impact of GPCRs in clinical medicine: Genetic variants and drug targets. Biochim Biophys Acta 2007; 1768: 994-1005.
27. Kobilka B,. Agonist binding: A multistep process. Mol Pharmacol 2004; 65: 1060-2.
28. Cernecka H, Ochodnicky P, Lamers WH, et al. Specificity evaluation of antibodies against human β3-adrenoceptors. Naunyn-Schmiedeberg's Arch Pharmacol 2012; 385: 875-82.
29. 3-adrenoceptor gene forms a well-conserved haplotype that is associated with moderate obesity and altered receptor function. Diabetes 1999; 48: 203-5.
30. Schneider T, Fetscher C, Michel MC,. Human urinary bladder strip relaxation by the β-adrenoceptor agonist isoprenaline: Methodological considerations and effects of gender and age. Frontiers Pharmacol 2011; 2: 11. DOI: 10.3389/fphar.2011.00011
31. Persson K, Pandita RK, Spitsbergen JM, et al. Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats. Am J Physiol 1998; 275: R1366-73.
32. Spitsbergen JM, Clemow DB, McCarty R, et al. Neurally mediated hyperactive voiding in spontaneously hypertensive rats. Brain Res 1998; 790: 151-9.
33. Steers WD, Clemow DB, Persson K, et al. The spontaneously hypertensive rat: Insight into the pathogenesis of irritative symptoms in benign prostatic hyperplasia and young anxious males. Exp Physiol 1999; 84: 137-47.
34. Michel MC, Heemann U, Schumacher H, et al. Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol 2004; 172: 1390-3.